Literature DB >> 19760424

[Interstitial lung disease in collagen vascular diseases. Diagnostic and therapeutic implications of non-specific interstitial pneumonia].

A Schnabel1, M Reuter.   

Abstract

Interstitial lung disease (ILD) is among the most common organ manifestations in collagen vascular diseases and can be a major determinant of the long-term prognosis. Early diagnosis rests mainly on spirometry, including measurement of the CO diffusion capacity, and high-resolution computed tomography (HRCT). The most common histopathology of ILD in collagen vascular diseases is the non-specific interstitial pneumonia (NSIP) pattern. It is distinguished from the usual interstitial pneumonia (UIP) pattern, which is most common in idiopathic lung fibrosis, by a significant inflammatory component, a distinct HRCT pattern, with often prominent ground-glass opacities, and a distinct cell pattern on bronchoalveolar lavage (BAL) with an often prominent lymphocyte component. Therapeutic experience is heterogeneous but evidence is accumulating suggesting that NSIP in the collagen vascular diseases is amenable to immunosuppression. Rapid clinical and/or radiological deterioration, reflecting inflammatory activity, appears to mark those patients who are most likely to benefit from cyclophosphamide therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19760424     DOI: 10.1007/s00393-009-0482-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  31 in total

1.  Cladribine in the treatment of systemic lupus erythematosus nephritis.

Authors:  V Kontogiannis; P C Lanyon; R J Powell
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations.

Authors:  Seth J Kligerman; Steve Groshong; Kevin K Brown; David A Lynch
Journal:  Radiographics       Date:  2009 Jan-Feb       Impact factor: 5.333

3.  Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.

Authors:  Bridget Griffiths; Sarah Miles; Hilary Moss; Rod Robertson; Douglas Veale; Paul Emery
Journal:  J Rheumatol       Date:  2002-11       Impact factor: 4.666

4.  A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis.

Authors:  Z D Daniil; F C Gilchrist; A G Nicholson; D M Hansell; J Harris; T V Colby; R M du Bois
Journal:  Am J Respir Crit Care Med       Date:  1999-09       Impact factor: 21.405

Review 5.  Idiopathic interstitial pneumonias: CT features.

Authors:  David A Lynch; William D Travis; Nestor L Müller; Jeffrey R Galvin; David M Hansell; Philippe A Grenier; Talmadge E King
Journal:  Radiology       Date:  2005-07       Impact factor: 11.105

Review 6.  Histopathology and bronchoalveolar lavage.

Authors:  R M Silver; A U Wells
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

7.  Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study.

Authors:  V D Steen; J K Lanz; C Conte; G R Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1994-09

8.  Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.

Authors:  Alice Bérezné; Brigitte Ranque; Dominique Valeyre; Michel Brauner; Yannick Allanore; David Launay; Véronique Le Guern; Jean-Emmanuel Kahn; Louis-Jean Couderc; Joël Constans; Pascal Cohen; Alfred Mahr; Christian Pagnoux; Eric Hachulla; André Kahan; Jean Cabane; Loïc Guillevin; Luc Mouthon
Journal:  J Rheumatol       Date:  2008-05-01       Impact factor: 4.666

9.  Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.

Authors:  A U Wells; P Cullinan; D M Hansell; M B Rubens; C M Black; A J Newman-Taylor; R M Du Bois
Journal:  Am J Respir Crit Care Med       Date:  1994-06       Impact factor: 21.405

10.  Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.

Authors:  Shikha Mittoo; Fredrick M Wigley; Robert Wise; Huiqing Xiao; Laura Hummers
Journal:  Arthritis Rheum       Date:  2007-12
View more
  1 in total

Review 1.  [Interstitial lung disease in polymyositis/dermatomyositis].

Authors:  A Schnabel
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.